EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Humoral and cellular immune responses after three or four doses of BNT162b2 in patients with hematological malignancies

Line Dam Heftdal iD, Sebastian Rask Hamm, Laura Pérez-Alós, Johannes Roth Madsen, Jose Juan Almagro Armenteros, Kamille Fogh, Christoffer Cronwald Kronborg, Anders Pommer Vallentin, Rasmus Bo Hasselbalch, Dina Leth Møller, Cecilie Bo Hansen, Mia Pries-Heje und 10 weitere

European Journal of Haematology · 2023-08 · 111 (2) · 229-239

DOI: 10.1111/ejh.13986 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Haematology, online erschienen am 08.05.2023. Verfasst von Line Dam Heftdal und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. Hauptthemen laut MEDLINE: Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, COVID-19, Hematologic Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Carlsbergfondet, Novo Nordisk Fonden, Svend Andersen Fonden.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Initial responses to coronavirus disease 2019 vaccination are impaired in patients with hematological malignancies. We investigated immune responses after three or four doses of BNT162b2 in patients with myeloid and lymphoid malignancies compared to controls, and identified risk factors for humoral and cellular nonresponse 1 year after first vaccination.

Methods

In 407 hematological patients (45 myeloid, 362 lymphoid) and 98 matched controls, we measured immunoglobulin G (IgG) and neutralizing antibodies specific for the receptor‐binding domain of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) at baseline, 3 weeks, 2, 6, and 12 months, and interferon‐γ release at 12 months.

Results

In patients with lymphoid malignancies, SARS‐CoV‐2 receptor‐binding domain IgG concentration and mean neutralizing capacity was lower than in controls at all time points. A diagnosis of chronic lymphocytic B‐cell leukemia (CLL) or lymphoma was associated with humoral nonresponse at 12 months compared to having multiple myeloma/amyloidosis ( p < .001 and p = .013). Compared to controls, patients with lymphoid malignancies had increased risk of cellular nonresponse. A lymphoma diagnosis was associated with lower risk of cellular nonresponse compared to patients with multiple myeloma/amyloidosis, while patients with CLL had comparable response rates to patients with multiple myeloma/amyloidosis ( p = .037 and p = .280).

Conclusions

In conclusion, long‐term humoral and cellular immune responses to BNT162b2 were impaired in patients with lymphoid malignancies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaLeukemia, Lymphocytic, Chronic, B-CellCOVID-19Hematologic NeoplasmsAmyloidosisHumansBNT162 VaccineSARS-CoV-2Immunoglobulin GImmunity, CellularAntibodies, ViralVaccination

Stichwörter der Autor:innen

BNT162b2booster dosecellular immune responsehumoral immune responselymphoid malignanciesmyeloid malignancies

Substanzen

BNT162 VaccineImmunoglobulin GAntibodies, Viral

Autor:innen und Institutionen

  • Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
  • Viro-Immunology Research Unit, Department of Infectious Diseases, Section 8632, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
  • Biotech Research and Innovation Centre, University of Copenhagen, Copenhagen, Denmark.
  • Laboratory of Molecular Medicine, Department of Clinical Immunology, Section 7631, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
  • Department of Genetics, Stanford University School of Medicine, Stanford, California, USA.
  • Department of Cardiology, Herlev and Gentofte Hospital, Copenhagen University Hospital, Copenhagen, Denmark.

ORCID-Profile: Line Dam Heftdal

Förderung

  • Carlsbergfondet
  • Novo Nordisk Fonden
  • Svend Andersen Fonden
  • Rigshospitalets Research Committee
  • The Danish Cancer Society
  • Danish Research Center for Precision Medicine in Blood Cancer
  • Greater Copenhagen Health Science Partners (Clinical Academic Group in Blood Cancers)
  • Kræftens Bekæmpelse

Zitieren

APA

Heftdal, L. D., Hamm, S. R., Pérez-Alós, L., Madsen, J. R., Armenteros, J. J. A., Fogh, K., Kronborg, C. C., Vallentin, A. P., Hasselbalch, R. B., Møller, D. L., Hansen, C. B., Pries-Heje, M., Gang, A. O., Ostrowski, S. R., Frikke-Schmidt, R., Sørensen, E., Hilsted, L., Bundgaard, H., Iversen, K., …, & Grønbaek, K. (2023). Humoral and cellular immune responses after three or four doses of BNT162b2 in patients with hematological malignancies. European Journal of Haematology, 111(2), 229-239. https://doi.org/10.1111/ejh.13986

Vancouver

Heftdal LD, Hamm SR, Pérez-Alós L, Madsen JR, Armenteros JJA, Fogh K, et al. Humoral and cellular immune responses after three or four doses of BNT162b2 in patients with hematological malignancies. European Journal of Haematology. 2023;111(2):229-239. doi:10.1111/ejh.13986

BibTeX
@article{Heftdal2023,
  author = {Heftdal, Line Dam and Hamm, Sebastian Rask and Pérez-Alós, Laura and Madsen, Johannes Roth and Armenteros, Jose Juan Almagro and Fogh, Kamille and Kronborg, Christoffer Cronwald and Vallentin, Anders Pommer and Hasselbalch, Rasmus Bo and Møller, Dina Leth and Hansen, Cecilie Bo and Pries-Heje, Mia and Gang, Anne Ortved and Ostrowski, Sisse Rye and Frikke-Schmidt, Ruth and Sørensen, Erik and Hilsted, Linda and Bundgaard, Henning and Iversen, Kasper and Garred, Peter and Nielsen, Susanne Dam and Grønbaek, Kirsten},
  title = {Humoral and cellular immune responses after three or four doses of BNT162b2 in patients with hematological malignancies},
  journal = {European Journal of Haematology},
  year = {2023},
  volume = {111},
  number = {2},
  pages = {229--239},
  doi = {10.1111/ejh.13986}
}
Kostenlos starten →